Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
TKM-080301
Arbutus Biopharma Corp
Hepatocellular Carcinoma
1 trial -
TKM-080301
Arbutus Biopharma Corp
Cancer
1 trial -
TL-895, TL-895
Lacuna Pharma Pty Ltd
B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
1 trial -
TL-895, TL-895, TL-895, TL-895 matching placebo, TL-895, TL-895
Lacuna Pharma Pty Ltd
Indolent Systemic Mastocytosis
1 trial -
TMC435
Elan Pharma International
Hepatitis C
1 trial -
TNO155, JDQ443, TNO155, VDT482/ BGB-A317, JDQ443, TNO155, TNO155
Novartis Pharmaceuticals
Advance solid tumors harboring the KRAS G12C mutation
1 trial -
TNX-102 SL
Tonix Pharmaceuticals Holding
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
1 trial -
TNX-1300
Tonix Pharmaceuticals Holding
Cocaine Intoxication
1 trial -
TNX-1500
Tonix Pharmaceuticals Holding
Kidney Transplant
1 trial -
TNX-1900
Tonix Pharmaceuticals Holding
Chronic Migraine
1 trial -
TNX-201
Tonix Pharmaceuticals Holding
Tension-Type Headache
1 trial -
TNX-601 ER
Tonix Pharmaceuticals Holding
Depression
1 trial -
TOCILIZUMAB , SECUKINUMAB , ANAKINRA , ADALIMUMAB , RITUXIMAB, USTEKINUMAB
Pari Pharma GmbH
Patients displaying a non-classified, severe and resistant inflammatory disease
1 trial -
TOCILIZUMAB, FLUDARABINE PHOSPHATE, YTB323, CYCLOPHOSPHAMIDE
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
1 trial -
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, LEE011, TEMOZOLOMIDE, TEMOZOLOMIDE
Novartis Pharmaceuticals
Relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma)
1 trial -
TP-03
Tarsus Pharmaceuticals
Meibomian Gland Dysfunction
1 trial -
TP-05 (lotilaner) Low Dose
Tarsus Pharmaceuticals
Lyme Disease
1 trial -
TP-38
Teva Pharma GmbH
Recurrent Glioblastoma Multiforme
1 trial -
TP-38
Teva Pharma GmbH
Glioblastoma Multiforme
1 trial -
TPM XR
SUPERNUS PHARMACEUTICALS, INC.
Epilepsy
1 trial -
TQB3616 capsules
Chia Tai Tianqing Pharmaceutical Group Co.,
HR-positive, HER2-negative Advanced Breast Cancer
1 trial -
TV-1380 150 mg
Teva Pharma GmbH
Cocaine Addiction
1 trial -
TV-45070
Teva Pharma GmbH
Osteoarthritis of the Knee
1 trial -
TV-45070
Teva Pharma GmbH
Postherpetic Neuralgia
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources